Cover Image
市場調查報告書

基因治療藥的R&D收益與預測:2018年∼2028年

Gene Therapy R&D and Revenue Forecasts 2018-2028

出版商 Visiongain Ltd 商品編碼 351066
出版日期 內容資訊 英文 134 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
基因治療藥的R&D收益與預測:2018年∼2028年 Gene Therapy R&D and Revenue Forecasts 2018-2028
出版日期: 2018年05月31日 內容資訊: 英文 134 Pages
簡介

全球基因治療市場,預計2018年∼2023年以41.1%的年複合成長率成長。

本報告提供全球基因治療市場相關調查分析,概要,主要的治療藥與預測,次市場,研發產品線分析與預測,主要企業等系統性資訊。

第1章 報告概要

第2章 基因治療的簡介

  • 所謂基因治療
  • 基因治療的種類
  • 報告除外產品
  • 基因治療載體

第3章 全球基因治療市場:主要的治療藥與預測

  • 全球基因治療市場:產品概要
  • Gendicine (rAd-p53)
  • Oncorine
  • Neovasculgen
  • Glybera
  • Strimvelis

第4章 全球基因治療市場與疾病次市場

  • 全球基因治療藥市場
  • 基因治療市場預測
  • 癌症的基因治療
  • 罕見疾病的基因治療
  • 心血管疾病的基因治療
  • 眼科疾病的基因治療
  • 其他疾病的基因治療

第5章 研發產品線分析與預測

  • 開發平台
  • 開發平台分析
  • Collategene (AMG0001):AnGes MG/Vical
  • BC-819:BioCancell
  • BC-821:BioCancell
  • Lenti-D:Bluebird Bio
  • LentiGlobin (LentiGlobin BB305):Bluebird Bio
  • SPK-RPE65:Spark Therapeutics
  • SPK-CHM:Spark Therapeutics
  • SPK-FIX:Spark Therapeutics/Pfizer
  • SPK-TPP1:Spark Therapeutics
  • Invossa (TissueGene-C):TissueGene Inc/Kolon Life Science
  • VM202-DPN:ViroMed
  • 重要的開發平台技術開發
  • CRISPR
  • 基因治療開發平台的未來

第6章 基因治療市場關注企業

  • UniQure
  • Biogen
  • Bluebird Bio
  • Spark Therapeutics
  • Applied Genetic Technologies Corporation
  • Oxford Biomedica
  • GenSight Biologics
  • 基因治療與大型製藥公司:聯盟

第7章 基因治療市場定性分析

  • SWOT分析
  • 主要國家市場:基因治療市場法規

第8章 結論

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0314

The gene therapy market is projected to grow at a CAGR of 41.1% in the first half of the forecast period. In 2018, the cancer treatment submarket accounted for 68.7% of the gene therapy drug market. Visiongain estimated that gene therapy for rare diseases will be the driver for market growth in the second half of the forecast period.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand-new 134 page report you will receive 72 charts- all unavailable elsewhere.

The 134-page report provides clear detailed insight into the gene therapy market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

image1

Report Scope

  • Gene Therapy market forecasts from 2018-2028
  • This report assesses the approved gene therapy products in the market and gives revenue to 2028 for Neovasculgen
  • Provides qualitative analysis and forecast of the submarket by indication for the period 2018-2028:
  • Cancer
  • Cardiovascular disorders
  • Rare diseases
  • Ophthalmological diseases
  • Other therapeutic uses
  • Profiles leading companies that will be important in the development of the gene therapy market. For each company, developments and outlooks are discussed and companies covered in this chapter include:
  • UniQure
  • Biogen
  • Bluebird Bio
  • Spark Therapeutics
  • Applied Genetics Technologies Corporation
  • Oxford Biomedica
  • GenSight Biologics
  • Assesses the outlook for the leading gene treatment R&D pipeline for 2018 and discusses technological progress and potential. Profiles appear for gene therapy drug candidates, with revenue forecasts for six leading agents:
  • SPK-RPE65 (Spark Therapeutics)
  • Collategene (AMG0001, AnGes MG/Vical)
  • Invossa (TissueGene-C, TissueGene Inc/Kolon Life Science)
  • BC-819 (BioCancell)
  • Lenti-D (Bluebird Bio)
  • GSK2696273 (GlaxoSmithKline)
  • Provides qualitative analysis of trends that will affect the gene therapies market, from the perspective of pharmaceutical companies, during the period 2018 to 2028. SWOT analysis is provided and an overview of regulation of the gene therapy market by leading region given.
  • Our study discusses factors that influence the market including these:
  • Translation of research into marketable products modifying human DNA - gene transfer for therapeutic use, altering the nuclear genome
  • Genomic editing technology and other supporting components
  • Collaborations to develop and launch gene-based products - acquisitions and licensing deals
  • Supporting technologies for human genetic modification, gene replacement and targeted drug delivery
  • Gene therapies for ophthalmologic diseases - next-generation medicines
  • Regulations in the United States, the European Union and Japan - overcoming technological and medical challenges to pass clinical trials.

Visiongain's study is intended for anyone requiring commercial analyses for the gene therapy market. You find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Global Gene Therapy Market Overview
  • 1.2 Benefits of This Report
  • 1.3 How This Report Delivers
  • 1.4 Key Questions Answered by This Analytical Report
  • 1.5 Who is This Report For?
  • 1.6 Methods of the Study
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Associated Visiongain Reports
  • 1.9 About Visiongain

2. Introduction to Gene Therapy

  • 2.1 What is Gene Therapy?
  • 2.2 Types of Gene Therapy
  • 2.3 Products Excluded from the Report
  • 2.4 Gene Therapy Vectors

3. Gene Therapy World Market: Leading Treatments and Forecasts, 2017-2028

  • 3.1 The World Market for Gene Therapy: Overview of Products
  • 3.2 Gendicine (rAd-p53) - The First Gene Therapy to Market
  • 3.3 Oncorine: Growth is Hindered by Certain Factors
  • 3.4 Neovasculgen: Russia's First Gene Therapy
    • 3.4.1 Neovasculgen: Historical Performance and Revenue Forecast, 2017-2028
  • 3.5 Glybera: A Drug with Promise
    • 3.5.1 Glybera: Pricing Ends the Dream to Become a Blockbuster Product
  • 3.6 Strimvelis: Second Gene Therapy for an Inherited Disease Ever to be approved for Sale and the First Corrective Gene Therapy for Children to be Approved Anywhere in the World
    • 3.6.1 Even Big Pharma Struggle in the Rare Disease Space

4. Gene Therapy World Market and Disease Submarkets, 2017-2028

  • 4.1 The Global Market for Gene Therapy Drug Treatments in 2017
  • 4.2 Gene Therapy Market Forecast, 2017-2028
  • 4.3 Gene Therapy for Cancer
    • 4.3.1 Clinical Trials for Cancer
    • 4.3.2 The Cancer Gene Therapy Treatment Submarket Forecast 2017-2028
  • 4.4 Gene Therapy for Rare Diseases
    • 4.4.1 The Rare Disease Treatment Submarket Forecast 2017-2028
  • 4.5 Gene Therapy for Cardiovascular Diseases
    • 4.5.1 The Cardiovascular Disease Treatment Submarket Forecast 2017-2028
  • 4.6 Gene Therapy for Ophthalmologic Diseases
    • 4.6.1 Advanced Stage Gene Therapies for Ophthalmologic Diseases
    • 4.6.2 The Ophthalmologic Disease Treatment Submarket Forecast 2017-2028
  • 4.7 Gene Therapy for Other Diseases
    • 4.7.1 The Other Disease Treatment Submarket Forecast 2017-2028
    • 4.7.2 Changing Market Shares: Cancer Disease Gene Therapies Will Dominate and Become Market Leader

5. R&D Pipeline Analysis and Forecasts, 2017-2028

  • 5.1 Pipeline
  • 5.2 Pipeline Analysis
  • 5.3 Collategene (AMG0001) - AnGes MG/Vical
  • 5.4 BC-819 - BioCancell
  • 5.5 BC-821 - BioCancell
  • 5.6 Lenti-D - Bluebird Bio
  • 5.7 LentiGlobin (LentiGlobin BB305) - Bluebird Bio
  • 5.8 SPK-RPE65 - Spark Therapeutics
  • 5.9 SPK-CHM - Spark Therapeutics
  • 5.10 SPK-FIX - Spark Therapeutics/Pfizer
  • 5.11 SPK-TPP1- Spark Therapeutics
  • 5.12 Invossa (TissueGene-C) - TissueGene Inc/Kolon Life Science
  • 5.13 VM202-DPN - ViroMed
  • 5.14 Important Pipeline Technology Developments
  • 5.15 Clustered regularly interspaced short palindromic repeats (CRISPR)
  • 5.16 The Future of the Gene Therapy Pipeline

6. Companies of Interest in the Gene Therapy Market: Robust Pipelines Will Yield Revenue in the Future

  • 6.1 UniQure- the First Commercial Stage Gene Therapy Company in the West
  • 6.2 Biogen - Focusing on Ophthalmologic and Rare Disease Gene Therapies
  • 6.3 Bluebird Bio: Gene Editing Technology
  • 6.4 Spark Therapeutics- Strong Change to Become the First Company with Marketed Gene Therapy in the US
  • 6.5 Applied Genetic Technologies Corporation: Specialisation in Ophthalmologic Diseases
  • 6.6 Oxford Biomedica: Collaboration as a Strategy
  • 6.7 GenSight Biologics - Novel Mitochondrial Technology Platform
  • 6.8 Gene Therapy and Big Pharma: Collaborations

7. Qualitative Analysis of the Gene Therapy Market, 2018-2028

  • 7.1 SWOT Analysis of the Gene Therapy Treatment Market, 2018
  • 7.2 Strengths: A Vast Pipeline for a Wide Range of Indications
  • 7.3 Weaknesses: Low Patient Populations Cannot Sustain Long-Term Growth
  • 7.4 Opportunities and Threats for the Gene Therapy Drug Market, 2018-2028
  • 7.5 Opportunities: Collaborations and Novel Technologies Will Pave the Way
  • 7.6 Threats: Expensive Drugs with Strict Regulations
  • 7.7 National Markets: Regulation of the Gene Therapy Market
    • 7.7.1 Gene Therapy Regulations: Evolving with the Market
    • 7.7.2 US Regulations: Strict Regulation of a Cautious Market
    • 7.7.3 EU Regulations: One Approval So Far
    • 7.7.4 Japanese Regulations: A Rigorous Process
    • 7.7.5 China Has Highest Gene Sequencing Capacity

8. Conclusions

  • 8.1 The World Gene Therapy Treatment Market: Current World Outlook
    • 8.1.1 Leading Gene Therapy Treatment Submarkets and Products, 2017-2028
    • 8.1.2 Driver for Growth to 2028: A Vast Pipeline of Gene Therapy Products
    • 8.1.3 Leading Regional Markets and Companies: Partnerships Will Achieve Success
  • 8.2 The Future of the Gene Therapy Treatment Market
  • Associated Visiongain Reports
  • Visiongain report sales order form
  • About Visiongain
  • Visiongain Report Evaluation Form

Table of Tables

  • Table 1.1 Foreign Currency Exchange Rates Utilised: Exchange Rate to $US, 2015, 2016, and 2017
  • Table 3.1 Approved Gene Therapies, 2017
  • Table 3.2 Gene Therapies in Pipeline, 2017
  • Table 3.3 Neovasculgen Historical Revenue Comparisons, Revenue ($m), AGR (%), 2013-2017
  • Table 3.4 Neovasculgen Forecast, Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 4.1 Leading Gene Therapy Drugs by Revenue ($m), 2017
  • Table 4.2 World Market Forecasts for Gene Therapy Drugs by Indication, Market Sizes ($m), Annual Growth Rates (%), CAGR (%), 2017-2028
  • Table 4.3 Selected Anti-Angiogenic Gene Therapy Using a Non-Viral Vector, 2017
  • Table 4.4 Selected Anti-Angiogenic Gene Therapy Using a Retroviral Vector, 2017
  • Table 4.5 Selected Anti-Angiogenic Gene Therapy Using an Adenoviral Vector, 2017
  • Table 4.6 Selected Anti-Angiogenic Gene Therapy Using an Adeno-Associated Virus Vector, 2017
  • Table 4.7 Selected Anti-Angiogenic Gene Therapy Using Lentiviral Vector, 2017
  • Table 4.8 Global Gene Therapy Clinical Trials by Indication, 2017
  • Table 4.9 Selected Cancer Gene Therapies in Phase 2 and Phase 3 Clinical Trial Development, 2017
  • Table 4.10 Selected Cancer Gene Therapies in Phase 1 and Phase 1/2 Clinical Trial Development, 2017
  • Table 4.11 Global Gene Therapy Market: Revenue ($m) and Market Shares (%) by Indication, 2017
  • Table 4.12 Global Market Forecast for Cancer Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2017-2028
  • Table 4.13 Rare Diseases Gene Therapy Pipeline, 2017
  • Table 4.14 Global Market Forecast for Rare Disease Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2017-2028
  • Table 4.15 Cardiovascular Gene Therapy Pipeline, 2017
  • Table 4.16 Global Market Forecast for Cardiovascular Disease Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2017-2028
  • Table 4.17 Preclinical Ophthalmologic Pipeline, 2017
  • Table 4.18 Clinical Ophthalmologic Pipeline, 2017
  • Table 4.19 Additional Products in the Clinical Ophthalmologic Pipeline, 2017
  • Table 4.20 Global Market Forecast for Ophthalmologic Disease Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2017-2028
  • Table 4.21 Global Market Forecast for Other Disease Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2017-2028
  • Table 4.22 Global Market Forecast for Gene Therapies by Indication: Market Shares (%), 2017-2022
  • Table 4.23 Global Market Forecast for Gene Therapies by Indication: Market Shares (%), 2023-2028
  • Table 5.1 Promising Gene Therapies in Development, 2018
  • Table 5.2 Gene Therapies in Phase 3, 2017
  • Table 5.3 Collatagene Forecast, Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 5.4 BC-819 Forecast, Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table5.5 Lenti-D Forecast, Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 5.6 SPK-RPE65 Forecast, Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 5.7 Invossa Forecast, Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 6.1 uniQure Pipeline, 2017
  • Table 6.2 Spark Therapeutics Collaborations, 2017
  • Table 6.3 Selected Big Pharma Collaborations in Gene Therapy, 2017
  • Table 7.1 Strengths and Weaknesses of the Gene Therapy Drug Treatment Market, 2017
  • Table 7.2 Gene Therapy Pipeline for Neurodegenerative Diseases, 2017
  • Table 7.3 Gene Therapy Pipeline for Metabolic Diseases, 2017
  • Table 7.4 Gene Therapy Pipeline for Musculoskeletal Diseases, 2017
  • Table 7.5 Gene Therapy Pipeline for Viral Diseases, 2017
  • Table 7.6 Opportunities and Threats of the Gene Therapy Drug Market, 2017
  • Table 7.7 Clinical Trials for Standard Drug Development Versus Orphan Drug Development, 2017
  • Table 8.1 Global Gene Therapy Drug Market Forecasts by Indication: Market Size ($m), Market Share (%), CAGR (%), 2017, 2022 and 2028

Table of Figures

  • Figure 1.1 Global Gene Therapy Market Segmentation Overview, 2017
  • Figure 2.1 Vectors Used in Gene Therapy Clinical Trials, 2017
  • Figure 3.1 Neovasculgen Forecast, Revenue ($m), 2017-2028
  • Figure 4.1 Gene Therapy World Market Forecast, Market Size ($m), AGR (%), 2017-2028
  • Figure 4.2 Global Gene Therapy Clinical Trials by Indication, 2017
  • Figure 4.3 Cancer Gene Therapy Pipeline by Phase of Development, 2017
  • Figure 4.4 Global Gene Therapy Market: Market Shares (%) by Indication, 2018
  • Figure 4.5 Global Market Forecast for Cancer Gene Therapies: Revenue ($m), 2017-2028
  • Figure 4.6 Rare Diseases Gene Therapy Pipeline by Phase of Development, 2017
  • Figure 4.7 Global Market Forecast for Rare Disease Gene Therapies: Revenue ($m), 2017-2028
  • Figure 4.8 Cardiovascular Gene Therapy Pipeline by Phase of Development, 2017
  • Figure 4.9 Global Market Forecast for Cardiovascular Disease Gene Therapies: Revenue ($m), 2017-2028
  • Figure 4.10 Global Market Forecast for Ophthalmologic Disease Gene Therapies: Revenue ($m), 2017-2028
  • Figure 4.11 Global Market Forecast for Other Disease Gene Therapies: Revenue ($m), 2017-2028
  • Figure 4.12 Global Market for Gene Therapy Drugs: Market Shares by Indication (%), 2022
  • Figure 4.13 Global Market for Gene Therapy Drugs: Market Shares by Indication (%), 2028
  • Figure 5.1 Gene Therapies in Clinical Development by Phase, 2017
  • Figure 5.2 Collategene Forecast, Revenue ($m), 2017-2028
  • Figure 5.3 BC-819 Forecast, Revenue ($m), 2017-2028
  • Figure 5.4 Lenti-D Forecast, Revenue ($m), 2017-2028
  • Figure 5.5 SPK-RPE65 Forecast, Revenue ($m), 2017-2028
  • Figure 5.6 Invossa Forecast, Revenue ($m), 2017-2028
  • Figure 5.7 Gene Therapy Market Strategy Analysis
  • Figure 5.8 Key Take Ways, Challenges and Application of CRISPR Market
  • Figure 5.9 Impact of CRISPR Technology on the Gene Therapy Market
  • Figure 8.1 Gene Therapy Drug Treatment Market Forecast by Indication: Market Sizes ($m), 2017, 2022, and 2028

COMPANIES LISTED

  • 4DMT (4D Molecular Therapeutics)
  • Abeona
  • AGTC (Applied Genetics Technologies Corporation)
  • AMT (Amsterdam Molecular Therapeutics)
  • AnGes MG
  • Asklepios BioPharma
  • AstraZeneca
  • Audentes Therapeutics
  • Avalanche Biotech
  • Bayer Healthcare
  • Beijing Northland Biotech Co
  • Benda Pharmaceutical
  • Benitec Biopharma
  • BioCancell
  • Biogen
  • Biogen Idec
  • Bluebird Bio
  • BMS (Bristol-Myers Squibb)
  • Broad Institute/Whitehead Institute
  • Celgene
  • Cell Therapy Catapult
  • Cellectis
  • Chiesi Farmaceutici
  • Clearside Biomedical
  • Convergence Pharmaceuticals
  • Daiichi Sankyo
  • Dimension Therapeutics
  • Editas Medicine
  • Fondazione Telethon
  • Francis Crick Institute
  • Genable Technologies Ltd
  • Genethon
  • GenSight Biologics
  • GenVec
  • Google
  • GSK (GlaxoSmithKline)
  • Henry Ford Health System
  • HSCI (Human Stem Cells Institute)
  • HSR-TIGET (San Raffaele Telethon Institute for Gene Therapy),
  • ImaginAb
  • Immune Design Corp
  • InoCard
  • Inovio
  • Intellia Therapeutics
  • Invetech
  • Kite Pharma
  • Kolon Group
  • Kolon Life Science
  • Lysogene
  • Mitsubishi Tanabe Pharma Corporation
  • Neuralgene
  • NightstaRx
  • Northwestern Memorial Hospital
  • Novartis
  • OXB (Oxford Biomedica)
  • Pfizer
  • PNP Therapeutics
  • Precision Genome Engineering Inc aka Pregenen
  • ProNai
  • Protek Group
  • Raffaele Hospital
  • REGENX Biosciences
  • Renova Therapeutics
  • Roche
  • Roszdravnadzor
  • Sangamo Biosciences
  • Sanofi
  • Sarepta Therapeutics
  • Shanghai Sunway Biotech
  • Shenzhen SiBiono GeneTech
  • Sotex Pharm Firm
  • Spark Therapeutics
  • SynerGene Therapeutics
  • Takara Bio
  • TAP Biosystems
  • Thermo Fisher Scientific
  • TissueGene
  • ToolGen
  • UC Berkeley
  • UC San Francisco
  • uniQure
  • US Business Innovation Network
  • Vertex Pharmaceuticals
  • Vical Incorporated
  • ViroMed
  • VM Biopharma
  • Voyage Therapeutics

List of Organisation Mentioned

  • ASCO (American Society of Clinical Oncology)
  • ASI (Agency for Strategic Initiatives)
  • CAT (Committee for Advanced Therapies)
  • CBER (Center for Biologics Evaluation and Research)
  • CHMP (Committee for Medicinal Products for Human Use)
  • CHOP (The Children's Hospital of Philadelphia)
  • DCGI (Drugs Controller General of India)
  • DHHS (Department of Health and Human Services)
  • EMA (European Medicines Agency)
  • FDA (US Food and Drug Administration)
  • INSERM (Institut National de la Santé et de la Recherche Médicale)
  • IRB (Institutional Review Boards)
  • MFDS (Korean Ministry of Food and Drug Safety)
  • MHLW (Ministry of Health, Labour, and Welfare)
  • MHRA (Medicines and Healthcare Products Regulatory Agency)
  • Ministry of Health Commission
  • NHS (National Health Service)
  • NICE (the National Institute for Health and Care Excellence)
  • NIH (National Institutes of Health)
  • OHRP (Office for Human Research Protections)
  • PMDA (Pharmaceuticals and Medical Devices Agency)
  • RCGM (Review Committee of Genetic Manipulation)
  • Russian Ministry of Healthcare and Social Development
  • SFDA (State Food and Drug Administration of China)
  • SMC (Scottish Medicines Consortium)
  • The Fund for Promotion of Small Innovative Enterprises in Science and Technology
  • The IGI (Innovative Genomics Initiative)
  • The Innovative Genomics Initiative
  • The Walter and Eliza Hall Institute
  • The Wellcome Trust Sanger Institute
  • WFH (World Federation of Hemophilia)
  • WHO (World Health Organization)
Back to Top